KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) FCF Margin (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed FCF Margin for 9 consecutive years, with 21.57% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 1102.0% year-over-year to 21.57%, compared with a TTM value of 6.65% through Dec 2025, up 212.0%, and an annual FY2025 reading of 6.65%, up 212.0% over the prior year.
  • FCF Margin was 21.57% for Q4 2025 at Teva Pharmaceutical Industries, up from 5.2% in the prior quarter.
  • Across five years, FCF Margin topped out at 23.89% in Q4 2023 and bottomed at 13.94% in Q1 2021.
  • Average FCF Margin over 5 years is 4.59%, with a median of 4.17% recorded in 2025.
  • The sharpest move saw FCF Margin tumbled -1800bps in 2021, then surged 1632bps in 2024.
  • Year by year, FCF Margin stood at 7.39% in 2021, then soared by 190bps to 21.4% in 2022, then increased by 12bps to 23.89% in 2023, then tumbled by -56bps to 10.55% in 2024, then soared by 104bps to 21.57% in 2025.
  • Business Quant data shows FCF Margin for TEVA at 21.57% in Q4 2025, 5.2% in Q3 2025, and 3.14% in Q2 2025.